Self-Immolative Linker Design for Stable Targeted Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugates face challenges with linkers that lack plasma and chemical stability, leading to unpredictable drug release and increased side effects, limiting their versatility and effectiveness.
Innovation Solution
A compound comprising a self-immolative group and a ligand-drug conjugate with a specific structure that includes a self-eliminating linker, enabling controlled drug release through enzymatic or chemical reactions, ensuring stability and targeted delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If a thioether linker is used in antibody-drug conjugates, then the conjugate structure is simple and easy to manufacture, but the chemical and plasma stability is low leading to unpredictable drug release
Solution Approach 1:
The linker is divided into multiple functional segments: a stable core structure (piperazine or piperidine ring), a self-immolative domain (containing hydrolyzable bonds), and a drug-release domain. This segmentation allows each part to perform its specific function - the core provides stability, the self-immolative domain controls release timing, and the drug-release domain enables targeted delivery.
Solution Approach 2:
A self-immolative group serves as an intermediary between the stable linker core and the drug molecule. This intermediary contains hydrolyzable bonds that are stable in plasma but can be cleaved by intracellular enzymes, mediating the transition from stable circulation to controlled drug release at the target site.
2Ease of operation
If a chemically separable linker (disulfide, hydrazone, or oxime bond) is used, then the drug can be released through chemical reactions, but the drug may dissociate at locations unrelated to the target site resulting in toxic side effects
Solution Approach 1:
The linker is designed with different chemical properties at different locations: the core structure has high chemical stability for plasma circulation, while the self-immolative domain contains specifically positioned hydrolyzable bonds that are susceptible to intracellular enzymes but resistant to plasma conditions. This local differentiation ensures site-specific drug release.
Solution Approach 2:
The linker's chemical stability parameters are optimized to create a threshold effect: stable under plasma conditions (pH 7.4, specific enzyme absence) but unstable under intracellular conditions (specific enzyme presence, different pH). This parameter change enables conditional drug release only at the target site.
3Reliability
If a linker is designed to be hydrolyzed by enzymatic reactions in target cells, then selective drug release at target cells can be achieved, but the plasma stability and chemical stability may be compromised
Solution Approach 1:
The linker transitions from a static stable structure to a dynamic system that responds to enzymatic conditions. The self-immolative domain remains inert during circulation but becomes activated upon encountering intracellular enzymes, dynamically switching from stable to unstable state to release the drug.
Solution Approach 2:
The linker combines multiple chemical moieties with different stability characteristics: a chemically stable core (resistant to plasma degradation) and an enzymatically labile self-immolative domain (susceptible to intracellular enzymes). This composite structure achieves both plasma stability and selective cellular release.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides a stable and controlled drug release mechanism, minimizing side effects and enhancing the versatility of antibody-drug conjugates for various antibodies and drugs.
Implementation Method 1
a linker that can be separated by a chemical method or hydrolyzed by an enzymatic reaction is mainly used
Implementation Method 2
the drug is dissociated through a mechanism such as 1,6-elimination or cyclization after hydrolysis by an enzymatic reaction
Implementation Method 3
the drug is dissociated through a mechanism such as 1,6-elimination or cyclization after hydrolysis by an enzymatic reaction
Data Source
AI summary
The present invention provides a compound comprising a self-immolative group and a ligand-drug conjugate comprising the same. According to the present invention, an active substance can be stably delivered to a target site, and the active substance can be rapidly released at the target site, thereby increasing the efficacy of the active substance, and the active substance can be inhibited from causing side effects at a location other than the target location.